Helus Pharma Inc. (HELP) Stock Price, Quote & News

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethyla...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 764 8385

Website: www.helus.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

DCcomet Aug. 8 at 3:26 PM

$HELP Average price target of $34

1 · Reply

Defen Aug. 7 at 11:52 PM

$HELP damn she’s a rolling

0 · Reply

cambruck7 Aug. 7 at 9:45 PM

$HELP what a damn week

0 · Reply

BRITLS Aug. 7 at 8:24 PM

$HELP going to have to unwind a bit before earnings. Things been running hot

1 · Reply

finck Aug. 7 at 8:07 PM

$HELP a great and promising week

0 · Reply

RuddyRolls Aug. 7 at 7:42 PM

$HELP indeed. A rising career of 3 separate billion dollar buy outs chooses wisely - and upwards. The last one was for$14.5B just last year. And to J & J - a very plausible contender to acquire HELP. Everybody who knows the game knows. Hence$20 in Sept inbound and no longer even sideways days on the chart.

0 · Reply

skratky Aug. 7 at 6:53 PM

$HELP Earnings Aug 11 for $HELP

0 · Reply

TalkMarkets Aug. 7 at 6:52 PM

Event-Driven #Biotech Bonanzas $HELP $INSM $IOVA $XBI $XLV https://talkmarkets.com/article/event-driven-biotech-bonanzas-1786128699

0 · Reply

BankOnTheFuture Aug. 7 at 5:41 PM

$HELP the ultimate contrary indicator!

0 · Reply

Plainolmike Aug. 7 at 5:07 PM

$HELP be nice to just get a little sideways movement for a few days to let the technicals cool off a bit

1 · Reply

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Jul 21, 2026, 7:50 AM EDT - 19 days ago

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Jun 29, 2026, 7:40 AM EDT - 5 weeks ago

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Jun 29, 2026, 7:00 AM EDT - 5 weeks ago

Cybin Annual report: Q4 2026

Jun 29, 2026, 7:00 AM EDT - 5 weeks ago

Cybin Earnings release: Q4 2026

Jun 29, 2026, 7:00 AM EDT - 5 weeks ago

Cybin Slides: Corporate presentation

Jun 25, 2026, 9:27 AM EDT - 6 weeks ago

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Jun 24, 2026, 6:01 AM EDT - 6 weeks ago

Helus Pharma™ Announces US$50 Million Underwritten Offering

Jun 24, 2026, 6:00 AM EDT - 6 weeks ago

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Jun 15, 2026, 7:00 AM EDT - 7 weeks ago

Cybin Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 11, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference

Jun 4, 2026, 2:35 PM EDT - 2 months ago

Cybin Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Apr 30, 2026, 7:17 PM EDT - 3 months ago

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 30, 2026, 7:30 AM EDT - 3 months ago

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Apr 28, 2026, 7:30 AM EDT - 3 months ago

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 23, 2026, 7:30 AM EDT - 3 months ago

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

Apr 20, 2026, 2:05 PM EDT - 3 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX GHRS

Apr 20, 2026, 8:15 AM EDT - 3 months ago

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Apr 20, 2026, 6:43 AM EDT - 3 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB GHRS

Apr 16, 2026, 7:30 AM EDT - 4 months ago

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Cybin Slides: Corporate presentation

Mar 12, 2026, 7:30 AM EDT - 5 months ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Mar 5, 2026, 7:30 AM EST - 5 months ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 5 months ago

Cybin Transcript: Study result

Mar 5, 2026, 7:30 AM EST - 5 months ago

Cybin Press release: Study result

Mar 5, 2026, 7:30 AM EST - 5 months ago

Cybin Slides: Study result

Feb 24, 2026, 7:45 AM EST - 5 months ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 17, 2026, 7:30 AM EST - 6 months ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 13, 2026, 12:30 PM EST - 6 months ago

Cybin Earnings release: Q3 2026

Feb 13, 2026, 7:31 AM EST - 6 months ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Dec 30, 2025, 3:33 PM EST - 7 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 19, 2025, 7:00 AM EST - 8 months ago

Cybin Registration statement: Registration Filing

Dec 18, 2025, 12:29 PM EST - 8 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Nov 17, 2025, 7:30 AM EST - 9 months ago

Cybin Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Cybin Earnings Call Transcript: Q2 2026

Nov 13, 2025, 8:00 AM EST - 9 months ago

Cybin Earnings release: Q2 2026

Nov 13, 2025, 7:20 AM EST - 9 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 9 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:30 PM EST - 9 months ago

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:30 AM EST - 9 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 2:00 PM EST - 9 months ago

Cybin Transcript: Future of Health Summit 2025

Nov 5, 2025, 7:30 AM EST - 9 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 9 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 10 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 10 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 11 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 17, 2025, 9:20 AM EDT - 11 months ago

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 8:00 AM EDT - 11 months ago

Cybin Registration statement: Registration Filing

Sep 11, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 11:00 AM EDT - 11 months ago

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:30 AM EDT - 11 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 5, 2025, 10:20 AM EDT - 1 year ago

Cybin Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 1 year ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 1 year ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 10:00 AM EDT - 1 year ago

Cybin Transcript: AGM 2025

Aug 13, 2025, 5:30 PM EDT - 1 year ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Cybin Earnings release: Q1 2026

Aug 12, 2025, 2:30 PM EDT - 1 year ago

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cybin Registration statement: Registration Filing

Jul 17, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 1 year ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 12:00 AM EDT - 1 year ago

Cybin Earnings release: Q4 2025

Jul 1, 2025, 12:00 AM EDT - 1 year ago

Cybin Annual report: Q4 2025

Jun 30, 2025, 10:03 PM EDT - 1 year ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

DCcomet Aug. 8 at 3:26 PM

$HELP Average price target of $34

1 · Reply

Defen Aug. 7 at 11:52 PM

$HELP damn she’s a rolling

0 · Reply

cambruck7 Aug. 7 at 9:45 PM

$HELP what a damn week

0 · Reply

BRITLS Aug. 7 at 8:24 PM

$HELP going to have to unwind a bit before earnings. Things been running hot

1 · Reply

finck Aug. 7 at 8:07 PM

$HELP a great and promising week

0 · Reply

RuddyRolls Aug. 7 at 7:42 PM

0 · Reply

skratky Aug. 7 at 6:53 PM

$HELP Earnings Aug 11 for $HELP

0 · Reply

TalkMarkets Aug. 7 at 6:52 PM

Event-Driven #Biotech Bonanzas $HELP $INSM $IOVA $XBI $XLV https://talkmarkets.com/article/event-driven-biotech-bonanzas-1786128699

0 · Reply

BankOnTheFuture Aug. 7 at 5:41 PM

$HELP the ultimate contrary indicator!

0 · Reply

Plainolmike Aug. 7 at 5:07 PM

$HELP be nice to just get a little sideways movement for a few days to let the technicals cool off a bit

1 · Reply

Buckwacker Aug. 7 at 4:52 PM

$HELP Dancing 🤗

0 · Reply

brunoq14 Aug. 7 at 4:16 PM

$HELP Just a reminder of what they said on June 29: "The Company intends to complete design of next HLP004 study by the end of Q3."

0 · Reply

Ridethesqueeze Aug. 7 at 3:37 PM

$HELP remember when everyone was absolutely crapping on the ticker symbol? A lot more digestible and clever when the stock is doing well.

0 · Reply

BoiBiotech Aug. 7 at 3:04 PM

$HELP Halstead decided to be CEO of this company because of the Pipeline potential. He would've never accepted it if there was a possibility of failure in the phase 3. That's why stock keep on rising.Somebody knows

2 · Reply

KitsenandPJ Aug. 7 at 2:44 PM

$HELP IS STILL HELPING MY PORTFOLIO!!

0 · Reply

Soulokash Aug. 7 at 2:22 PM

$HELP does anyone in here think this hits 50 to 60 this year ? Or is that just ghouls or goblins ? The actual medication is far superior than what CMPS is doing from what I am reading online.

3 · Reply

Horseman23 Aug. 7 at 2:21 PM

$HELP something is cookin

0 · Reply

BoiBiotech Aug. 7 at 2:20 PM

$HELP I Need somebody,Help!

0 · Reply

Horseman23 Aug. 7 at 2:16 PM

$HELP

0 · Reply

RuddyRolls Aug. 6 at 8:21 PM

$HELP Sept$20S Q4 strong data read out $40-$60 CMPS approval >> add another $20

0 · Reply

Buckwacker Aug. 6 at 5:50 PM

$HELP If you’re a bear here you should really have a hard self anlyisis , shorting a company that’s working the system the way it is attended There’s so many bad guys to go after, short away but I have a bunch of vets and buddies who really need… Well help…

1 · Reply

cambruck7 Aug. 6 at 3:45 PM

$HELP

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	864,772
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A